drugset / Trial / NCT00533546
Activated Protein C in Acute Stroke Trial
Phase 2
Terminated
12 enrolled
University of Rochester
National Heart, Lung, and Blood Institute (NHLBI) · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this research study is to determine the safety and learn more about the dose of Activated Protein C (APC) in reducing the damage from stroke.
Timeline
- Start
- 2007-09
- Primary completion
- 2010-10
- Completion
- 2010-10
Outcome
Outcome not reported
Stopped (Enrollment): “Lack of recruitment”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | 10 ug/kg | Intravenous |
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | 15 ug/kg | Intravenous |
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | 22 ug/kg | Intravenous |
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | 33 ug/kg | Intravenous |
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | 50 ug/kg | Intravenous |
| Subject | Drotrecogin alfa (activated) | Protein / enzyme biologic | 75 ug/kg | Intravenous |